European Journal of Cancer
Volume 41, Issue 18 , Pages 2812-2818 , December 2005

Making sense of antisense

Received 9 June 2005 ,Accepted 9 June 2005.

References 

  1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280–284
  2. Cioffi CL, Garay M, Johnston JF, et al. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmacol. 1997;51:383–389
  3. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999;59:3143–3151
  4. Ru K, Schmitt S, James WI, et al. Growth inhibition and antimetastatic effect of antisense poly-DNP-RNA on human breast cancer cells. Oncol Res. 1999;11(11–12):505–512
  5. Zuker M. On finding all suboptimal folding of an RNA molecule. Science. 1989;244:48–52
  6. Vickers TA, Koo S, Bennett CF, et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis Dean NM, Baker BF. J Biol Chem. 2003;278:7108–7118
  7. Crooke T. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta. 1999;1489:31–44
  8. Gewirth AM. Oligonucleotide therapeutics: a step forward. J Clin Oncol. 2000;18:1809–1811
  9. Fjose A, Ellingsen S, Wargelius A, et al. RNA interference: mechanisms and applications. Biotechnol Annu Rev. 2001;7:31–57
  10. Hannon GJ. RNA interference. Nature. 2002;418:244–251
  11. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21:635–637
  12. Moss EG, Taylor JM. Small-interfering RNAs in the radar of the interferon system. Nat Cell Biol. 2003;5:771–772
  13. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5:834–839
  14. Perez JR, Li Y, Stein CA, et al. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA. 1994;91:5957–5961
  15. Boggs RT, McGraw K, Condon T, et al. Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucl Acid Drug Dev. 1997;7:461–471
  16. Biroccio M, Leonetti C, Zuppi G. The future of antisense therapy: combination with anticancer treatments. Oncogene. 2003;22:6579–6588
  17. Agrawal S, Jiang Z, Zhao Q, et al. Mixed-backbone oligonucleotides as second generation antisense oligonulcleotides. In vitro and in vivo studies. Proc Natl Acad Sci USA. 1997;94:2620–2625
  18. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucl Acid Drug Dev. 1997;7:187–195
  19. Sheehan JP, Phan TM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry. 2001;40:4980–4989
  20. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137–1141
  21. Leslie M, Coulthardt SA, Plummer ER, et al. Decreased expression of DNMT 1 at the mRNA level following 7 day infusion of the antisense compound MG98 in a phase I study. EJC. 2004;2:133
  22. Stevenson JP, Yao KS, Gallagher M, et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS5132 (CGP 69846A). J Clin Oncol. 1999;17:2227–2236
  23. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2000;6:1655–1663
  24. Zellweger T, Miyake H, Cooper S, et al. Ethyl chemistry. Antitumour activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy) ethyl chemistry. J Pharmacol Exp Ther. 2001;298:934–940
  25. Chi KN, Eisenhauer E, Fazli L, et al. A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′ methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Proc Am Soc Clin Oncol. 2004;23:203
  26. Kirkwood JM, Bedikian AY, Millwars MJ, et al. Long-term survival results of a randomized multinational phase 3 of dacarbazine (DTIC) with or without bcl-2 antisense (oblimersen sodium)in patients with advanced malignant melanoma. Proc Am Soc Clin Oncol. 2005;23:711

PII: S0959-8049(05)00795-1

doi: 10.1016/j.ejca.2005.06.029

European Journal of Cancer
Volume 41, Issue 18 , Pages 2812-2818 , December 2005

Article Tools

* Image Usage & Resolution